Placebo-controlled study examining effects of selegiline in children
with attention-deficit/hyperactivity disorder
by
Rubinstein S, Malone MA, Roberts W, Logan WJ.
Division of Neurology, Brain and Behaviour Programme,
The Hospital for Sick Children, Toronto, Ontario, Canada.
J Child Adolesc Psychopharmacol. 2006 Aug;16(4):404-15.

ABSTRACT

Ahere is evidence suggesting a role for dopamine in attention-deficit/hyperactivity disorder (ADHD). Pharmacological treatments that act on the dopamine system have been successful in reducing ADHD symptoms. However, unlike traditional stimulants (i.e., methylphenidate), selegiline is a monoamine oxidase inhibitor (MAOI) that has been shown to reduce ADHD symptoms without producing undesirable side effects. In this study using a randomized, double- blind, placebo-controlled, crossover design, cognitive tasks and behavioral rating scales were administered to measure the effectiveness of selegiline in treating different symptoms of ADHD in 11 children aged 6-13. Results indicate that selegiline may target specific symptoms of ADHD including: sustained attention, the learning of novel information, hyperactivity, and peer interactions. Because the drug was not associated with negative side effects and did not specifically reduce symptoms of impulsivity, selegiline may be a preferred treatment for individuals who present with the primarily inattentive subtype of ADHD.

ADHD
MAOIs
Review
Selegiline
Selegiline N-oxide
Alzheimer's disease
Selegiline and MDMA
Selegiline and nitric oxide
Amphetamine metabolites
Selegiline / neuroprotection
Selegiline and life-expectancy
Selegiline as an immunostimulant
Selegiline enhances rodent erections
Selegiline for attention-deficit/hyperactivity disorder

Refs
HOME
HedWeb
Cocaine.org
BLTC Research
Paradise-Engineering
The Hedonistic Imperative
MDMA: Utopian Pharmacology